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study, was to test for antibacterial activity of a green alga,
Caulerpa sertularioides from the Persian Gulf.
Methods: The extract from C. sertularioides was pre-
pared by 20minutes boiling of alga in 20% glycerine solution
and it was then sterilized using the ﬁlteration. A bacterial
concentration of 500000 colony forming units (CFU)/ml of
Staphylococcus epidermidis (ATCC 14990) as a gram posi-
tive or Escherichia coli (ATCC 25922) as a gram negative
bacterium were tested with different concentrations of the
extract in Mueller-Hinton broth for evaluation of antibacte-
rial effect. Controls without the extract were treated by the
same way. Results. The extract showed antibacterial activ-
ity against S. epidermidis and E. coli in the concentrations
of 34mg/ml and 27.2mg/ml, respectively.
Conclusion: C. sertularioides could be a suitable source
for isolation of antibacterial compounds and furthert in-vivo
investigations.
doi:10.1016/j.ijid.2008.05.1063
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Background: Beta-lactam antibiotics efﬁcacy depends on
the duration of time in which serum concentration exceeds
MIC. The aim of open prospective randomized study was to
compare clinical and microbiolgical efﬁcacy of continuous
infusion versus intermittent administration of meropenem
in critically ill patients.
Methods: Patients admitted to interdisciplinary ICU
suffering from severe infection indicated to meropenem
administration were randomized to receive either a 2 g
iv loading dose of meropenem followed by a daily 4 g
continuous infusion (CONTINUOUS group) or intermittent
administration of 2 g of meropenem iv in every 8 h
(INTERMITTENT group). Antibiotic therapy was stopped at
improvement of clinical state and signs of subsidence of
infection (body temperature below 38,3 ◦C, white blood
count <10000/mm3 or decrease below 25% of maximal value,
C-reactive protein - CRP ≤100mg/l). Microbiological efﬁ-
cacy was evaluated as success (eradication or presumed
eradication) or failure (persistence or rezistence devel-
opment). The age, gender, APACHE II score, SOFA score,
length of ICU stay, length of mechanical ventilation, type
of infection were assessed. Success, failure and length of
meropenem therapy and total dose of meropenem were
evaluated. Mann-Whitney, unpaired t-test and Chi-squared
test were used accordingly; p < 0,05 was considered statis-
tically signiﬁcant.
Results: A total of 84 patients (55 men and 29 women)
were enrolled and randomized in CONTINUOUS (n = 42)
and INTERMITTENT (n = 44) group. No signiﬁcant differ-
ences between CONTINUOUS and INTERMITTENT group in
assessed parameters were found except for total dose of
meropenem.
Conclusion: Continuous infusion and intermittent admin-
istration of meropenem in critically ill patients provided
equivalent clinical and microbiological outcome. Compared
with intermittent application, continuous infusion signif-
icantly decreased the total dose of meropenem. Grant
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Background: In 2005, tigecycline (TIG) a novel glycylcy-
cline was approved in the US for treatment of complicated
skin and skin structure infections (cSSSI) and complicated
intra-abdominal infections (cIAI). As such, it is important to
continue to monitor TIG activity against target pathogens for
these indications. This study reports the in vitro activity of
TIG against Enterobacteriaceae (EN) and Acinetobacter spp.
(AC) as observed during development (‘01—‘04), and during
the years following its approval for use (‘05, ‘06 and ‘07).
The results were further stratiﬁed to determine whether any
potential variability in TIG activity against EN and AC exists
according to patient location (PL) and specimen source (SS).
Methods: EN and AC isolates were collected from mul-
tiple locations across all nine US Bureau of Census regions
during the following years (Y): ‘01—‘04 (EN: 1330, AC: 224),
‘05 (EN: 1151, AC: 77), ‘06 (EN: 958, AC: 255), and ‘07 (EN:
599, AC: 114). Isolates were centrally tested using broth
microdilution according to current CLSI standards. TIG activ-
ity was analyzed by patient location (PL; outpatient [OP],
intensive-care unit [ICU], and inpatient non-ICU [IP]) and by
specimen source (SS; blood [BL], respiratory [RP], urine [UR:
EN only], and skin and skin structure [SST]). EN FDA break-
points (BPs) were used to interpret all TIG MIC results (as
BPs for TIG against AC do not currently exist).
Results: Against EN overall, TIG had an MIC90 of 1mg/L
in each study period (‘01—‘04, ‘05, ‘06, and ‘07), and EN
isolates were ≥99% susceptible (S) to TIG throughout. The
activity of TIG for each study period was consistent by MIC90,
regardless of PL (MIC90 = 1mg/L against OP, ICU, and IP) or
SS (MIC90 = 1mg/L against BL, RP, and SST, 0.5—1mg/L for
UR isolates). In the most recent period evaluated (‘07), EN
isolates were ≥99% S to TIG for all PL and SS evaluated.
Against AC overall, TIG had an MIC90 of 2mg/L in ‘01—‘04
and ‘07 and 1mg/L in ‘05 and ‘06. The % S of AC went from
97% in ‘01—‘04 to ≥99.5% in ‘05, ‘06 and ‘07. For each study
period, little variation in TIG MIC90 was observed either by
PL or SS (1—2mg/L). In ‘07, 100% of tested acinetobacter
were susceptible to TIG (EN BPs were utilized for AC).
Conclusion: Little to no alteration in the in vitro activ-
ity of TIG against EN and AC was apparent by MIC90 over the
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years of study which span its introduction to use in 2005. The
activity by MIC90 was also consistent in each study period,
regardless of the PL and SS of the tested isolates. Contin-
ued surveillance is warranted both to support the further
clinical development of TIG and to detect any emerging
resistance among target pathogens for indications which TIG
is currently approved (cSSSI and cIAI).
doi:10.1016/j.ijid.2008.05.1065
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Background: Dalbavancin is a novel lipoglycopeptide with
an extended half-life and intended for treating complicated
skin and skin structure infections caused by S. aureus (SA)
and -haemolytic streptococci (BHS). The DECIDE Program
was initiated to assess the activity of dalbavancin compared
to vancomycin or teicoplanin (Italy only) against recent
(2007) clinical isolates from across Europe (EU).
Methods: Eighteen sites in France, Germany, Spain, Italy
and UK utilized standardized, reference-quality agar diffu-
sion methods including Etest and CLSI (M2-A9) disk diffusion
(DD) tests with concurrent QC (CLSI M100-S18, 2008). 1,127
strains were tested against dalbavancin and comparison
glycopeptides by Etest. DD was used for linezolid, cefox-
itin, levoﬂoxacin, gentamicin, tetracycline, erythromycin,
clindamycin (plus D-test), penicillin and ceftriaxone. Dalba-
vancin susceptibility was deﬁned at ≤0.25mg/L.
Results: Dalbavancin exhibited potent activity
against the SA and coagulase-negative staphylococci
(CoNS; MIC50/90, 0.064/0.19mg/L), and BHS (MIC50/90,
≤0.016/0.047mg/L). Overall, vancomycin and teicoplanin
were ≥eight-fold less potent. Italy had higher dalbavancin
MIC values (two-fold) for SA and the highest MRSA rate
(44%) compared to other nations (8—36%). Dalbavancin
MIC90 values were slightly higher for group B (0.047mg/L)
compared to group A (0.032mg/L) streptococci. Nearly 4%
of BHS isolates were levoﬂoxacin-non-susceptible. Among
SA, resistance rates were: erythromycin (29%), clindamycin
(13%), gentamicin (10%), and levoﬂoxacin (29%) with
higher resistance rates among MRSA. Inducible clindamycin
resistance was high among SA (72%) and CoNS (48%) and
less among BHS (25%). Rare strains had non-susceptible MIC
values for linezolid (0.3%) and vancomycin (0.1%)
Conclusions: Dalbavancin demonstrated pronounced
activity (MIC, ≤0.25mg/L) against staphylococci and BHS
from European countries. Due to dalbavancin’s high molec-
ular weight, like other peptides, care must be taken
when interpreting Etest-generated MICs (false resistance).
Dalbavancin provides coverage of contemporary Gram-
positive pathogens, including resistant isolates recovered
from patients in Europe, conﬁrming earlier USA reports.
doi:10.1016/j.ijid.2008.05.1066
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Background: Ertapenem is a relatively new carbapenem
with broad activity. There are however limited studies
regarding its efﬁcacy in bacteremic patients. We evalu-
ated the in-vitro activity of Ertapenem against blood culture
isolates (community onset and nosocomial) at a tertiary hos-
pital.
Methods: Bacteria isolated from blood cultures from
hospitalized patients admitted to the National University
Hospital, Singapore (Dec 2003—May 2004) were identiﬁed
using the Vitek instrument (bioMerieux, NC) and Microbact
12A and 12B (Oxoid Australia). Gram-stain, catalase, coag-
ulase (Pastorex Staph Plus, Bio-Rad, CA) and PYR disk
testing were done for Staphylococcusand Streptococcus spp.
Ertapenem susceptibilities were determined using the Kirby-
Bauer disk method on cation-adjusted Mueller-Hinton plates
according to the CLSI performance standards. Burkholderia
pseudomallei (B. pseudomallei) isolates were further tested
using the E-test (AB Biodisk, Sweden).
Results: 333 blood stream isolates were studied,
including 157 Enterobacteraciae (73 Extended spectrum
beta-lactamase (ESBL) positive) and 29 isolates of B. pseudo-
mallei. All 157 Enterobacteraciae isolates were Ertapenem
susceptible. 26 B. pseudomallei strains were susceptible
and 3 strains intermediate to Ertapenem by disk testing,
but the E-test showed that only 5 of the 29 strains were
susceptible (MIC≤2mcg/ml). Of the non-fermenting gram-
negatives, 26 of 64 isolates were susceptible (including 4/6
B. cepacia, 8/26 A. baumanii and 3/10 P. aeruginosa iso-
lates). All isolates of S. maltophila (9/9) were resistant. Of
the gram-positives, 2/2 L. monocytogenes and all S. viridans
(5/5), beta-hemolytic Streptococci (11/11), S. pneumoniae
(6/6), methicillin susceptible S. aureus (32/32) were sus-
ceptible. All 12 strains of penicillin susceptible E. faecalis
were non-susceptible to Ertapenem, whilst 9 of the 10 B.
fragilis strains tested were
Conclusions: Ertapenem demonstrates excellent activity
against enterobacteraciae including ESBL producing strains
at our institution but is lacking against A. baumannii, P.
aeruginosa, S. maltophilia and E. faecalis. It also has poor
activity against B. pseudomallei and cannot be recom-
mended as therapy for melioidosis.
doi:10.1016/j.ijid.2008.05.1067
